India Globalization Capital (NYSE: IGC) Shows Potential for Strong Market Valuation Growth
- India Globalization Capital recently acquired exclusive patent rights for the use of low-dose THC as a potential therapeutic agent for Alzheimer’s disease
- No other publicly traded cannabis pharmaceutical company has a patent filing for a potential Alzheimer’s treatment
- Costs associated with Alzheimer’s disease top $236 billion in the U.S. and $600 billion globally
India Globalization Capital, Inc. (NYSE MKT: IGC), a Maryland-based company, is currently preparing four products for medical trials, including Hyalolex for the treatment of Alzheimer’s disease. Alzheimer’s is a fatal, progressive brain disease that slowly destroys memory and thinking.
Alzheimer’s is the leading cause of dementia and the third-leading cause of death in the U.S. Treatment outlooks have been bleak, as there is currently no cure, no way to prevent the disease, and no long-term treatment for the disease. However, India Globalization Capital may well improve the outlook for Alzheimer’s patients with a novel cannabis-based pharmaceutical therapy.
From an investment standpoint, IGC’s potential for market valuation growth is striking due to the size of the market for a successful Alzheimer’s treatment. Other companies in the cannabis space and also those focused on treatments for Alzheimer’s are valued in the hundreds of millions – and even billions – of dollars.
A definitive licensing agreement with the University of South Florida makes IGC the exclusive licensee of a U.S. patent filing titled, “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” The patent filing targets amyloid beta plaques, believed to be the cause of Alzheimer’s disease. The patent asserts that a newly discovered pathway allows low doses of THC to bind to amyloid beta plaques and keep them from accumulating on neurons, thus impacting the disease’s notorious cognitive decline. Be sure to view the CNN video on IGC’s website for additional information- http://www.igcinc.us/alzheimers-disease-1.
India Globalization Capital is preparing other phytocannabinoid-based pharmaceutical therapies for medical trials that target nausea and vomiting in AIDS and cancer patients; sleep disorders, anxiety and dyskinesia in Parkinson’s patients; and seizures in dogs and cats.
In addition, the company is developing treatments aimed at neuropathic and cancer pain, epilepsy, PTSD, end-of-life supportive care, and therapies for chronic neurological and cancer diagnoses.
India Globalization Capital is a first mover in the area of cannabis-based combination therapy and has filed for six patents in large market treatments including pain, eating disorders and epilepsy. Patents have been filed for a pain medication in the U.S., Canada and Europe, and upcoming filings include therapies aimed at PTSD, depression, Alzheimer’s and Parkinson’s disease.
For more information, visit www.IGCInc.us
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- India Globalization Capital recently acquired exclusive patent rights for the use of low-dose THC as a potential therapeutic agent for Alzheimer’s disease
- No other publicly traded cannabis pharmaceutical company has a patent filing for a potential Alzheimer’s treatment
- Costs associated with Alzheimer’s disease top $236 billion in the U.S. and $600 billion globally
India Globalization Capital, Inc. (NYSE MKT: IGC), a Maryland-based company, is currently preparing four products for medical trials, including Hyalolex for the treatment of Alzheimer’s disease. Alzheimer’s is a fatal, progressive brain disease that slowly destroys memory and thinking.
Alzheimer’s is the leading cause of dementia and the third-leading cause of death in the U.S. Treatment outlooks have been bleak, as there is currently no cure, no way to prevent the disease, and no long-term treatment for the disease. However, India Globalization Capital may well improve the outlook for Alzheimer’s patients with a novel cannabis-based pharmaceutical therapy.
From an investment standpoint, IGC’s potential for market valuation growth is striking due to the size of the market for a successful Alzheimer’s treatment. Other companies in the cannabis space and also those focused on treatments for Alzheimer’s are valued in the hundreds of millions – and even billions – of dollars.
A definitive licensing agreement with the University of South Florida makes IGC the exclusive licensee of a U.S. patent filing titled, “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” The patent filing targets amyloid beta plaques, believed to be the cause of Alzheimer’s disease. The patent asserts that a newly discovered pathway allows low doses of THC to bind to amyloid beta plaques and keep them from accumulating on neurons, thus impacting the disease’s notorious cognitive decline. Be sure to view the CNN video on IGC’s website for additional information- http://www.igcinc.us/alzheimers-disease-1.
India Globalization Capital is preparing other phytocannabinoid-based pharmaceutical therapies for medical trials that target nausea and vomiting in AIDS and cancer patients; sleep disorders, anxiety and dyskinesia in Parkinson’s patients; and seizures in dogs and cats.
In addition, the company is developing treatments aimed at neuropathic and cancer pain, epilepsy, PTSD, end-of-life supportive care, and therapies for chronic neurological and cancer diagnoses.
India Globalization Capital is a first mover in the area of cannabis-based combination therapy and has filed for six patents in large market treatments including pain, eating disorders and epilepsy. Patents have been filed for a pain medication in the U.S., Canada and Europe, and upcoming filings include therapies aimed at PTSD, depression, Alzheimer’s and Parkinson’s disease.
For more information, visit www.IGCInc.us
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
